NEW YORK, NY--(Marketwire - Mar 12, 2012) - The anticoagulant market continues to skyrocket as an aging population requires prevention from stroke and systemic embolism. While Warfarin has long dominated the anticoagulant market, several pharmaceutical companies are researching and developing new types of drugs that do not carry the same risks for uncontrolled bleeding as Warfarin to compete in the stroke prevention market. Five Star Equities examines the outlook for companies in the Healthcare sector and provides equity research on Momenta Pharmaceuticals Inc. (NASDAQ: [ MNTA ]) and Sunpeaks Ventures, Inc. (OTCBB: [ SNPK ]). Access to the full company reports can be found at:

[ www.fivestarequities.com/MNTA ]

[ www.fivestarequities.com/SNPK ]

According to a report released by Global Industry Analysts, Inc., the global anticoagulants market is projected to surpass $11.2 billion by the year 2015, driven by an aging global population, rising incidence of cardiovascular diseases, cancers, and acute hip and knee complications, as well as emergence of innovative therapeutics targeting new and previously targeted clotting factors.

Irena Melnikova, PhD, an analyst with TVM Capital in Boston, Massachusetts, wrote in Nature Reviews that the growth in anti-coagulants is being driven by the aging population, increased incidence of cardiovascular disease, and the availability of new medications.

Five Star Equities releases regular market updates on the Healthcare sector so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at [ www.fivestarequities.com ] and get exclusive access to our numerous stock reports and industry newsletters.

Sunpeaks Ventures, Inc. subsidiary Healthcare Distribution Specialists, LLC owns and markets Clotamin, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin. "By my calculations, if Sunpeaks is able to penetrate just 5% of the Warfarin market in just the U.S., sales for Clotamin could potentially surpass $25 million dollars annually," Mackie A. Barch, CEO of Sunpeaks said in a press release.

Part of Momenta Pharmaceuticals' pipeline includes M118 a "next generation" anticoagulant engineered to address the unmet needs in acute coronary syndrome, according to the company's website.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: [ www.fivestarequities.com/disclaimer ]